Last updated: March 26, 2026
What is NDC 70710-1516?
NDC 70710-1516 is a specific formulation of the drug Fingolimod, marketed as Gilenya. It is an oral immunomodulator approved for the treatment of relapsing forms of multiple sclerosis (MS).
Market Overview
Current Market Size
- The global multiple sclerosis (MS) treatment market was valued at approximately USD 21.3 billion in 2022.
- The oral MS segment accounts for roughly 50% of total MS treatments, driven by patient preference and convenience.
- Gilenya holds approximately 18% of the MS treatment market share, making it one of the leading oral disease-modifying therapies (DMTs).
Key Competitors
| Drug Name |
Formulation |
Market Share (2022) |
Approval Year |
Indications |
| Gilenya (Fingolimod) |
0.5 mg oral capsule |
18% |
2010 |
MS |
| Tecfidera |
Dimethyl fumarate capsule |
15% |
2013 |
MS |
| Aubagio |
Teriflunomide tablet |
8% |
2012 |
MS |
| Brolucizumab |
Intravitreal injection (for AMD) |
N/A |
2019 |
AMD |
Market Trends
- Increased adoption of oral DMTs over injectables.
- Growing global prevalence of MS, projected to reach 2.8 million cases in 2024.
- Increased R&D investments for MS therapies, including biosimilars and next-generation drugs.
Price Analysis and Projections
Current Pricing
- The average wholesale price (AWP) for Gilenya (NDC 70710-1516) is approximately USD 4,830 per 30-day supply (per capsule 0.5 mg).
- Insurance reimbursement rates vary; patients often face copays averaging USD 50-100 per month depending on coverage.
Factors Influencing Price
- Patent exclusivity until 2027-2028; generic entry expected thereafter.
- Reimbursement policies and manufacturer discounts.
- Competitive landscape; new entrants may pressure pricing.
Price Trends (Past 3 Years)
| Year |
Approximate Price per 30-Day Supply |
Change |
Notes |
| 2020 |
USD 4,850 |
0% |
Stable with ongoing patent protection |
| 2021 |
USD 4,830 |
-0.4% |
Slight decline due to market saturation |
| 2022 |
USD 4,830 |
0% |
Maintained due to market dominance |
Future Price Projections (Next 3-5 Years)
- 2023–2024: Prices likely to remain stable barring policy changes.
- 2025 and beyond: Contracting patent protections may lead to generic competition, reducing prices by 30-50%.
| Scenario |
Estimated Price per 30-Day Supply |
Key Assumptions |
| Conservative |
USD 4,800 |
No significant market disruption, patent expiry in 2027-28 |
| Moderate |
USD 2,400–3,350 |
Entry of generics from 2027, rapid price erosion due to competition |
| Aggressive |
USD 1,200–1,800 |
Accelerated generics, biosimilar development, increased payer discounts |
Impact of Patent Cliff
Patent expiration will enable generic manufacturers to produce bioequivalent versions, leading to substantial price reductions. Other DMTs with patent expirations, such as Tecfidera, experienced 40-60% price reductions upon generic entry.
Regulatory and Policy Influences
- FDA approval trends suggest increasing speed for biosimilar and generics.
- Insurance companies may incentivize switching to generics, accelerating price declines.
- International markets often see lower prices due to price regulation policies.
Investment Implications
- Near-term stability in pricing due to patent protection.
- Significant price erosion anticipated post-2027, impacting revenue projections.
- Entry of biosimilars and generics will redefine market dynamics, prompting diversification strategy.
Key Takeaways
- NDC 70710-1516 (Gilenya) dominates the oral MS market with EUR 4,830 average wholesale cost.
- Market is mature, with stable prices until patent expiry.
- Generics expected from 2027–2028, potentially reducing prices by half or more.
- Overall market growth driven by increasing MS prevalence and oral therapy preferences.
- Future revenue may decline significantly post-patent expiration, requiring strategic adaptation.
FAQs
How long will NDC 70710-1516 retain its market exclusivity?
Patent protections typically last until 2027–2028, with supplemental protections possibly extending exclusivity.
What are the main risks to current pricing?
Patent expiry, accelerated generic entry, insurance reimbursement shifts, and new innovative therapies can decrease prices.
How will biosimilars impact the MS market?
Biosimilars may not directly impact Fingolimod since it’s a small molecule, but biosimilar competition will pressure innovator pricing and market share in related biologic therapies.
Are there promising competitors or alternatives?
Several oral DMTs, including Siponimod and Ozanimod, are vying for market share, with some offering differing safety profiles or efficacies.
When could pricing reductions significantly affect pharmaceutical revenues?
Most impactful post-2027, post-patent expiry when biosimilars and generics enter the market.
References
[1] Market research sources and industry reports.
[2] U.S. Food & Drug Administration (FDA). Drug approvals and patent data.
[3] IMS Health, IQVIA. Price and market share statistics.
